News | Radiation Therapy | December 11, 2019

Stanford University Medical Center to Acquire Second Accuray CyberKnife M6 System

New system will be used to treat diseases in the brain and base of the skull

#ASTRO Accuray Incorporated announced today Stanford University Medical Center has selected a second CyberKnife M6 System to expand access to precise radiosurgery treatments to more of their patients

December 11, 2019 — Accuray Incorporated announced today Stanford University Medical Center has selected a second CyberKnife M6 System to expand access to precise radiosurgery treatments to more of their patients. With its installation, the hospital's clinicians will have a CyberKnife System dedicated to the treatment of diseases in the brain and base of the skull, making it possible for the existing system to be used to treat more patients with tumors elsewhere in the body. The new CyberKnife System will be installed at the Stanford Neuroscience Health Center, a comprehensive facility offering integrated outpatient services in one location designed to provide more accurate diagnoses, organized care, better quality of life and improved outcomes for the patient.

"We value our long-standing partnership with the Stanford clinical team, one of the most respected in the world, and are proud that they are using the CyberKnife System to improve the outcomes of people diagnosed with serious medical conditions," said Joshua H. Levine, president and CEO at Accuray. "At Accuray, our goal is to provide clinicians with a system that makes it as easy as possible for them to provide the best possible outcome for their patients, based on each patient's unique condition. Over the course of our relationship with the Stanford team, they have acquired four CyberKnife Systems, reinforcing their continued confidence in the system and demonstrating that we are delivering on our goal." 

"This year marks 25 years since the world's first patient was treated with a prototype CyberKnife System at Stanford. While clinicians at our hospital have used some version of the system since that time, a dedicated system located in our neuroscience center will enable us to provide precise and accurate SRS treatments to significantly more patients," said Steven D. Chang, M.D., co-director, Stanford Surgical Neuro-Oncology Program, Co-Director, Stanford CyberKnife Program, Stanford University School of Medicine. "The introduction of the CyberKnife System changed the way diseases or tumors in the head are treated. The system established multi-session or fractionated treatment as a standard for cranial stereotactic radiosurgery, a technique that has brought meaningful benefits to patients and the medical field."

The CyberKnife System was designed to deliver stereotactic radiosurgery (SRS) without a rigid frame bolted to the patient's head, which some other systems use to prevent movement during treatment. It provides a precise and effective option for patients with diseases or tumors in the brain requiring single or multi-session treatments, and younger patients who would not be candidates for treatment with a fixed head frame. Since its introduction, advanced new functionality, including the VOLO Optimizer, has been added to the CyberKnife System, enabling clinicians to treat patients significantly faster, without sacrificing the precision or accuracy for which the system is known.

SRS typically involves the delivery of a single high-dose radiation treatment or a few fractionated radiation treatments (usually up to five treatments) to destroy all tissue within the tumor. The ability to deliver high doses of radiation in a single or a few fractions is called hypofractionation. Hypofractionation can only be undertaken with systems that are able to target the tumor with extreme precision and accuracy, as the CyberKnife System can, while minimizing delivered dose to surrounding healthy tissue. The CyberKnife System has been proven to deliver radiation to the skull with sub-millimeter accuracy (to within 1.0mm of the target)1, meaning minimal radiation is delivered to the surrounding healthy brain tissue.

The CyberKnife System is routinely used to treat conditions in the brain including, but not limited to, benign and malignant primary tumors, brain metastases, trigeminal neuralgia, acoustic neuromas and arteriovenous malformations (AVMs). CyberKnife radiosurgery is even used to treat complicated neurosurgical cases, while maximally sparing brain tissues involved in important functions such as hearing and vision.

For more information: www.accuray.com

Related Content

An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.